However he's a bit older than others, like Raquel Leviss, who is only 28 . EMEA +44 20 7330 7500. RA Capital makes no guarantees as to their accuracy or completeness. Adisons primary responsibilities are to coordinate calendars, events, and company meetings for the Investment Team. Max DeNies is a Senior Associate with the TechAtlas division of RA Capital Management. Prior to RA, Christy was a Senior Scientist in Oncology Target Discovery at Pfizer. Zach works on both public and private investments and serves as a Board Director for Adagio Medical, Exo Imaging, LENZ Therapeutics, Nkarta Therapeutics, and Sydnexis. Sophie was a principal investigator in the Early Phase Trials Team at GSTT and has extensive experience in the delivery of early to late phase oncology trials. Prior to RA, Ryan was at KPMG where he was a Senior Associate. Prior to Q32 Bio, Maryann worked as the Operations Manager for Surface Oncology and several other biotech start-up companies from discovery research through end of Phase 2 Clinical trials. Early in his career, Mr. Grau worked with multi-national pharma companies including Pharmacia, Pharmacia & Upjohn, and Eisai as a management consultant focused on corporate strategy, M&A, and new product launch. Jacqueline has a BS with a double major in Molecular and Cellular Biology & Earth and Planetary Sciences from Johns Hopkins University. He served on the Board of Global Science and Technology for the National Academy of Sciences, is the author of The Entrepreneurs Guide to a Biotech Startup, and frequently writes and speaks on the future of biotechnology innovation. Christinas previous experience includes Stem Cell Program Manager at the Broad Institute and Deputy Editor at Cell Stem Cell. Previously in his career, he served as Associate General Counsel at Millennium Pharmaceuticals (now Takeda Oncology) where he built the legal department and led internal legal activities supporting several transformative pharmaceutical partnerships, a substantial global patent estate, and the companys IPO. Peter served on the Board of Global Science and Technology for the National Academy of Sciences and writes about the biotech social contract. In this role he works closely with RAs Venture Team to evaluate various drug discovery platforms and initiate novel therapeutics programs. Prior to RA, Kevin was a postdoctoral associate at the Broad Institute of MIT and Harvard and an EMBO fellow. Most recently, she was as an Entrepreneur-in-Residence at RA Ventures and was a Scientific Co-Founder and Associate Director of Corporate Development at Athenen Therapeutics (merged into Eliem Therapeutics; ELYM). In this role he works closely with RAs Venture Team to evaluate various drug discovery platforms and initiate novel therapeutics programs. Special Projects Operations Manager/Chief of Staff. Merediths primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Laura has a BS in Human Services; Clinical Concentration and a Minor in Disabilities Studies from the University of Delaware. She also gained administrative and client services experience in roles she held at Life Time Athletic, EF Education First, and at Beth Israel Deaconess Hospital ICU. Becca has a BA in Biology from Colgate University and a PhD in Biology from MIT. Lucas holds a BA in Criminal Justice and Philosophy from John Jay College of Criminal Justice in NY, a JD, Privacy Concentration, from Northeastern University School of Law, and is admitted to practice law in MA. His laboratory at the Broad focused on advanced high throughput biotechnology tools including DNA synthesis, single cell analysis, synthetic biology derived biomolecule libraries, and microbiome profiling. After joining RA Ventures as Chief Development Officer, Ed built the development team, oversaw development of six compounds from discovery-stage through to clinical-stage, and led the formation of several new companies, including Lusaris Therapeutics. Kyle also recently retired as a Colonel in the US Army Reserve after 24 years of service. She previously served as Senior Vice President, R&D Operations & New Product Planning at Epirium Bio. Peter Pan Is The Real Villain: Disney Supports The Evil Peter Pan Theory Biohaven Closes Second Tranche Of Private Placement And Appoints Two Before transitioning to industry, Cosmas was a faculty member at Harvard Medical School/Massachusetts General Hospital (MGH), where he had an active gastroenterology clinical practice and ran a lab whose research centered on fundamental aspects of RNA and epigenetics. Asthas primary responsibility is to identify needs for process improvement in the firm's data analytics and then both build and implement automated solutions. Anas previous experience includes Research Assistant positions at Massachusetts Eye and Ear Hospital, the Lupus Clinic/Renal Department at the BU Medical Center, and Harvard University Department of Molecular and Cellular Biology. Kyle was also the CEO and co-founder of Liquid Light, developer of a proprietary process to make major chemicals from CO2, which was sold to Avantium in 2016. Peter Kolchinsky, Ph.D. Board Member Peter Kolchinsky, Ph.D., has more than 18 years of experience in healthcare investing and is the founder of and a managing partner at RA Capital. Samuel Chowdhury is a Software Engineerat RA Capital Management. He has served on the Board of Directors of Sojournix, Inc., AltusPharmaceuticals (Nasdaq: ALTU) and the CellScape Corporation. She also held research roles at MIT, Children's Hospital, Harvard, and Brigham and Women's Hospital. Sonias primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Candice Galvez is an Executive Assistant at RA Capital Management. Cristina holds a BA in Molecular Biology with a minor in Business from Washington University in St. Louis, and a PhD in Microbiology and Molecular Genetics from Harvard University. Kaleens primary responsibility is to oversee the initiation, planning, and execution of various projects within the TechAtlas Division. Daniels primary responsibilities include creating competitive landscapes of climate change solutions and analyzing investment opportunities across climate technology and applied biotech. Prior to joining RA, Brigid was the Head of Venture Investments for BHP Ventures, the internal venture capital unit within the worlds largest mining company, where her investment mandate was to help the decarbonization of BHPs operations and to improve the sustainability of resource extraction. Walter Dauksher is a Junior Associate within the Planetary Health division of RA Capital Management. Craig holds a BA in Political Science from Bridgewater State College and a JD from Boston College Law School. Let us know if you like it and we may post more pieces with this option.) James McArthur is an Advisor for RA Capital Management. Daniel Slesinski is an Associate within the Planetary Health division at RA Capital Management. Most recently, Brian served as Analyst, Biotech/Pharma/Specialty Pharma at Tamarack Capital Management. Kathryn holds a BA in Geography and Peace and Conflict Studies from Colgate University, a MSc in International Development: Environment and Development from the University of Manchester (UK), and a MA and Ph.D. in Geography from Clark University (2016). Peter Kolchinsky Number of IPOs: 18. Michael Calore is the Director of Investor Relations at RA Capital Management. Shan Shan holds a PhD in Neuroscience from Harvard University and a BS in Brain and Cognitive Sciences from MIT. Daniel Bahcheli is an Associate Director at RA Capital Management. Steve's survey is fascinating. Alex has a BA with a triple-major in Finance, Economics, and Math from UMass Lowell. Raj holds a BA from Cornell University, where he majored in Chemistry. Previously, Laura covered hematologic malignancies, cell therapies, retinal diseases, and orphan neurodevelopmental disorders. Emorys primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Analysis: Top Biotech VC Investors in 2021 Based on - Insider Jennas primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. He completed the Executive Program at Stanford University, Graduate School of Business, as well as the Executive to Leader Institute at Korn/Ferry International. in Biomedical Anthropology from the University of Pennsylvania. Cosmas Giallourakis is a Venture Partner at RA Ventures, focusing on new company creation. Kevin Grosselin is RA Ventures Associate at RA Ventures (RAVen). As Executive Director of Business Development at Celgene, Emily was responsible for all aspects of deal evaluation, negotiation, and execution for licensing deals, mergers and acquisitions, and collaborations, with a focus on immune-inflammatory and neurodegenerative diseases. As a founder and member of Constellations executive team Patrick materially contributed to several successful financing rounds and deals, including a crossover round, an IPO and the ultimate acqusition of the company. From 1990- 1997, he held investment, business development, R&D, and marketing positions at DuPont Ventures. Brendan has more than 18 years of experience as a tax professional. Joe DeMaio is IT Operations Associate at RA Capital Management. Joel is currently a Venture Partner at RA Ventures focusing on new company creation. Alex comes to RA from Mirai Advisory, where he specialized in financial risk and data science and developed machine learning algorithms to support banks managing regulatory and operational challenges. Erich Scheller is the Director of the TechAtlas division of RA Capital Management. She holds a BS in Finance from Elon University and an MBA from Babson College. Tess Cameron is a Principal on the Investment Team at RA Capital Management. Habib has earned his Director Professionalism Certificate from the National Association of Corporate Directors. Ben previously worked as a Research Assistant in a Neuroinflammation lab at Brigham and Womens Hospital/Harvard Medical School, and was an Internet Application Developer at the Gallup Organization. In this role, he gained broad expertise across all phases of drug discovery, early development, and clinical research. Derek DiRocco is a Partner at RA Capital Management. He was named an MIT Technology Review 100 innovators under 35 for his MIT Media Lab social enterprise, Dimagi, that has impacted millions with its mobile data collection platform. Prior to RA, Laura was a Principal at MP Healthcare Venture Management.